Phase I study of bosutinib, a Src/Abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors

Adil I. Daud, Smitha S. Krishnamurthi, Mansoor N. Saleh, Barbara J. Gitlitz, Mitesh J. Borad, Philip J. Gold, Elena G. Chiorean, Gregory M. Springett, Richat Abbas, Shefali Agarwal, Nathalie Bardy-Bouxin, Poe Hirr Hsyu, Eric Leip, Kathleen Turnbull, Charles Zacharchuk, Wells A. Messersmith

Research output: Contribution to journal › Article › peer-review

80 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Phase I study of bosutinib, a Src/Abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science